Large bio­phar­ma com­pa­nies cull about 40 im­muno-on­col­o­gy pro­grams over the last two quar­ters

Clin­i­cal tri­al fail­ures, pa­tient en­roll­ment strug­gles, new pri­or­i­ties and a trans­formed FDA are just a few of the rea­sons why some of the top bio­phar­ma com­pa­nies de­cid­ed to cut about 40 dif­fer­ent im­muno-on­col­o­gy de­vel­op­ment pro­grams over the last two quar­ters, an SVB Se­cu­ri­ties analy­sis shows — con­firm­ing more than a half dozen End­points News ar­ti­cles.

As­traZeneca, Bris­tol My­ers Squibb, Roche, Janssen, Bay­er, Pfiz­er, Gilead, Ab­b­Vie and Mer­ck KGaA all cut 21 dif­fer­ent IO pro­grams linked to a va­ri­ety of new and fol­low-on in­di­ca­tions, ac­cord­ing to SVB Se­cu­ri­ties’ tal­ly for Q4.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER